IL12 is a potent immunotherapeutic drug that can activate CD8+ T cells and natural killer (NK) cells, enhance their tumor cell‐killing abilities, and interfere with the differentiation of regulatory T (Treg) cells. Here, CD8A is linked to neoplasm.